EP1718669A4 - Identification of novel ige epitopes - Google Patents

Identification of novel ige epitopes

Info

Publication number
EP1718669A4
EP1718669A4 EP04779424A EP04779424A EP1718669A4 EP 1718669 A4 EP1718669 A4 EP 1718669A4 EP 04779424 A EP04779424 A EP 04779424A EP 04779424 A EP04779424 A EP 04779424A EP 1718669 A4 EP1718669 A4 EP 1718669A4
Authority
EP
European Patent Office
Prior art keywords
identification
ige epitopes
novel ige
novel
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04779424A
Other languages
German (de)
French (fr)
Other versions
EP1718669A1 (en
Inventor
Sanjaya Singh
Danyang Huang
Sek Chung Michael Fung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/002894 external-priority patent/WO2004070011A2/en
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of EP1718669A1 publication Critical patent/EP1718669A1/en
Publication of EP1718669A4 publication Critical patent/EP1718669A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
EP04779424A 2004-02-02 2004-07-29 Identification of novel ige epitopes Withdrawn EP1718669A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2004/002894 WO2004070011A2 (en) 2003-02-01 2004-02-02 HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
PCT/US2004/002892 WO2004070010A2 (en) 2003-02-01 2004-02-02 A method for generating high affinity antibodies
PCT/US2004/024360 WO2005075504A1 (en) 2004-02-02 2004-07-29 IDENTIFICATION OF NOVEL IgE EPITOPES

Publications (2)

Publication Number Publication Date
EP1718669A1 EP1718669A1 (en) 2006-11-08
EP1718669A4 true EP1718669A4 (en) 2007-10-10

Family

ID=34841291

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04779424A Withdrawn EP1718669A4 (en) 2004-02-02 2004-07-29 Identification of novel ige epitopes

Country Status (8)

Country Link
EP (1) EP1718669A4 (en)
JP (1) JP2008507474A (en)
KR (4) KR101365375B1 (en)
CN (1) CN102702359A (en)
AU (2) AU2004315197B2 (en)
CA (1) CA2552999A1 (en)
SG (2) SG183683A1 (en)
WO (1) WO2005075504A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019131A2 (en) * 2006-08-04 2008-02-14 The Trustees Of The University Of Pennsylvania Methods and compositions for treating ige-mediated diseases
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JP2010519194A (en) * 2007-02-15 2010-06-03 アストラゼネカ・アクチエボラーグ Binding elements for IgE molecules
AR065368A1 (en) * 2007-02-15 2009-06-03 Astrazeneca Ab ANTIBODIES FOR IGE MOLECULES
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
CL2008003808A1 (en) * 2007-12-21 2011-03-11 Glaxosmithkline Biologicals Sa Malaria vaccine component comprising an rts, s and / or an immunogenic particle that is derived from the cs protein of one or more strains of p. vivax and hepatitis b antigen s or an immunogenic particle comprising rts, csv-s and optionally the unbound antigen s and a stabilizing agent; and vaccine.
SG10201400388QA (en) 2008-12-09 2014-05-29 Pfizer Vaccines Llc IgE CH3 peptide vaccine
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2018129248A1 (en) 2017-01-06 2018-07-12 The Regents Of The University Of California Therapeutic anti-ige antibodies and methods and compositions thereof
CN112203724A (en) * 2018-03-26 2021-01-08 诺华股份有限公司 Methods of treating chronic idiopathic urticaria using Rigeuzumab
EP4355362A1 (en) 2021-06-14 2024-04-24 Novartis AG Pharmaceutical formulation containing an anti-ige antibody

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
EP0957111A2 (en) * 1998-04-09 1999-11-17 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
WO2000023477A2 (en) * 1998-10-20 2000-04-27 University Of Sheffield Immunoglobulin variants
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
WO2000074716A2 (en) * 1999-06-08 2000-12-14 Smithkline Beecham Biologicals S.A. Ige peptides for allergy immunotherapy
WO2002016409A2 (en) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
WO2002034288A2 (en) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccine for treating allergy
EP1262491A2 (en) * 2001-05-22 2002-12-04 Pfizer Products Inc. Non-anaphylactogenic IgE vaccines
WO2003092714A2 (en) * 2002-04-30 2003-11-13 Glaxosmithkline Biologicals S.A. Peptide variants of ige constrained by beta-lactam bond

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69333484T2 (en) * 1992-09-24 2005-03-24 Novartis Ag Reshaped monoclonal antibodies against an immunoglobulin isotype
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
ES2566778T3 (en) * 2003-02-01 2016-04-15 Tanox, Inc. High affinity anti-human IgE antibodies

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
EP0957111A2 (en) * 1998-04-09 1999-11-17 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
WO2000023477A2 (en) * 1998-10-20 2000-04-27 University Of Sheffield Immunoglobulin variants
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
WO2000074716A2 (en) * 1999-06-08 2000-12-14 Smithkline Beecham Biologicals S.A. Ige peptides for allergy immunotherapy
WO2002016409A2 (en) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
WO2002034288A2 (en) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccine for treating allergy
EP1262491A2 (en) * 2001-05-22 2002-12-04 Pfizer Products Inc. Non-anaphylactogenic IgE vaccines
WO2003092714A2 (en) * 2002-04-30 2003-11-13 Glaxosmithkline Biologicals S.A. Peptide variants of ige constrained by beta-lactam bond

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG T W ET AL: "MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN IGE-PRODUCING B CELLS A POTENTIAL THERAPEUTIC FOR IGE-MEDIATED ALLERGIC DISEASES", BIO-TECHNOLOGY (NEW YORK), vol. 8, no. 2, 1990, pages 122 - 126, XP009084134, ISSN: 0733-222X *
MACGLASHAN D W ET AL: "DOWN-REGULATION OF FCEPSILONRI EXPRESSION ON HUMAN BASOPHILS DURINGIN VIVO TREATMENT OF ATOPIC PATIENTS WITH ANTI-IGE ANTIBODY", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, 1997, pages 1438 - 1445, XP002930932, ISSN: 0022-1767 *
See also references of WO2005075504A1 *

Also Published As

Publication number Publication date
AU2004315197A1 (en) 2005-08-18
AU2009202408A1 (en) 2009-07-09
AU2004315197B2 (en) 2009-06-04
KR20070008578A (en) 2007-01-17
KR101581659B1 (en) 2015-12-31
SG183683A1 (en) 2012-09-27
WO2005075504A1 (en) 2005-08-18
KR20130088198A (en) 2013-08-07
KR101365375B1 (en) 2014-02-19
JP2008507474A (en) 2008-03-13
SG149892A1 (en) 2009-02-27
KR101562114B1 (en) 2015-11-20
CA2552999A1 (en) 2005-08-18
KR20140021058A (en) 2014-02-19
CN102702359A (en) 2012-10-03
EP1718669A1 (en) 2006-11-08
KR20120056297A (en) 2012-06-01

Similar Documents

Publication Publication Date Title
IL176940A0 (en) IDENTIFICATION OF NOVEL IgE EPITOPES
GB0412973D0 (en) Identification of antibody producing cells
ZA200609595B (en) Novel CIS-Imidazolines
IL179730A0 (en) Novel cis-imidazolines
EP1778618A4 (en) Synthesis of triethylenetetramines
IL211491A0 (en) 4-(benzimidazolylmethylamino)-benzamidines
TWI372750B (en) Novel hydroxy-6-heteroarylphenanthridines
EP1756092A4 (en) Novel inhibitors of rho-kinases
IL179811A0 (en) Identification of tumors
EP1869192A4 (en) Framework-shuffling of antibodies
EP1965341A4 (en) Card capable of authentication
EP1711484A4 (en) Synthesis of cyanoimino-benzoimidazoles
HK1081282A1 (en) Chronograph
GB0426160D0 (en) Production of proteins
EP1718669A4 (en) Identification of novel ige epitopes
IL183106A0 (en) Production of proteins
HK1087494A1 (en) Wristwatch case
ZA200610303B (en) Novel cis-imidazolines
IL178184A0 (en) Synthesis of pyrrole-2-carbonitriles
GB0505985D0 (en) Nail aid
ZA200606635B (en) Novel isoamido-substituted hydroxy-6-phenylphenanthridines
AU158223S (en) Wristwatch
GB0408865D0 (en) Novel benzoxazocines
GB0424519D0 (en) Identification of micro-organisms
GB0413479D0 (en) Novel antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20070912

17Q First examination report despatched

Effective date: 20090407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130625